Newsroom | 8891 results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of pati...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones. Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology,...

BOSTON--(BUSINESS WIRE)--Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology. Quantitative coronary plaque analysis...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. “We are delighted to welcome Maria to our Board of Directors,” said Pulse Biosciences’ Co-Chairman of the Board Robert W. Duggan. “She brings an exceptionally strong track record...

BORDEAUX, France--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of a €35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI Tech4Cure1, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader. In total, FineHeart has secured €83 million in financing comb...

JERSEY CITY, NEW JERSEY--(BUSINESS WIRE)--Organon a annoncé aujourd’hui avoir conclu un accord avec Daiichi Sankyo Europe pour commercialiser Nilemdo® (acide bempédoïque) en France, au Danemark, en Islande, en Suède, en Finlande et en Norvège. Nilemdo® est un nouveau médicament, premier de sa catégorie, indiqué pour les patients présentant un taux de cholestérol élevé et un risque de maladie cardiovasculaire. Il offre un traitement alternatif aux patients qui ne peuvent pas être traités efficac...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Vandaag maakte Organon bekend dat het bedrijf een akkoord heeft gesloten met Daiichi Sankyo Europe voor de commercialisering van Nilemdo® (bempedoïnezuur) in Frankrijk, Denemarken, IJsland, Zweden, Finland en Noorwegen. Nilemdo® is een nieuw geneesmiddel van topkwaliteit, aangewezen voor patiënten met een hoge cholesterol en met risico voor cardiovasculaire aandoeningen. Het biedt een alternatieve behandeling voor patiënten die niet doeltreffend met statines...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon oggi ha annunciato la sigla di un accordo con Daiichi Sankyo Europe relativo alla commercializzazione di Nilemdo® (acido bempedoico) in Francia, Danimarca, Islanda, Svezia, Finlandia e Norvegia. Nilemdo® è un nuovo farmaco first in class indicato nei pazienti ipercolesterolemici e a rischio cardiovascolare, e rappresenta una terapia alternativa per i pazienti che non possono essere trattati efficacemente con le statine.ii "Questa collaborazione...

JERSEY CITY, Nueva Jersey--(BUSINESS WIRE)--Organon acaba de anunciar la firma de un acuerdo con Daiichi Sankyo Europe para comercializar Nilemdo® (ácido bempedóico) en Francia, Dinamarca, Islandia, Suecia, Finlandia y Noruega. Nilemdo® es un nuevo fármaco, el primero de este tipo, indicado para pacientes con colesterol alto y riesgo de padecer enfermedades cardiovasculares. Supone un tratamiento alternativo para pacientes que no puedan ser tratados eficazmente con estatinasii. «Esta colaboraci...

JERSEY CITY, New Jersey--(BUSINESS WIRE)--Organon gab heute bekannt, dass es eine Vereinbarung mit Daiichi Sankyo Europe über die Vermarktung von Nilemdo® (Bempedoinsäure) in Frankreich, Dänemark, Island, Schweden, Finnland und Norwegen geschlossen hat. Nilemdo® ist ein neues, erstklassiges Medikament, das für Patienten mit hohem Cholesterinspiegel und Herz-Kreislauf-Risiko indiziert ist. Es bietet eine alternative Behandlung für Patienten, die mit Statinen nicht wirksam behandelt werden können...